FIGURE 2
Patient’ s hands 6 months after initiating semaglutide demonstrating resolution of psoriatic arthritis symptoms.
DISCUSSION
GLP-1 RAs are well-established therapies for managing T2DM and obesity, with growing evidence supporting their broader systemic effects, including modulation of inflammatory pathways. 2, 3 PsA is a chronic, immune-mediated arthropathy affecting approximately 2.4 million people in the United States and is frequently associated with metabolic comorbidities such as obesity and insulin resistance. ⁴ The therapeutic landscape for PsA has evolved considerably, progressing from conventional treatments such as non-steroidal anti-inflammatory drugs and glucocorticoids to more advanced options, including conventional synthetic disease-modifying antirheumatic drugs( csDMARDs), biological DMARDs( bDMARDs), and targeted synthetic DMARDs( tsDMARDs). 5 Despite this evolution in treatment options, approximately 40 % of PsA patients experience only partial response or fail to respond to these therapeutic approaches, highlighting the urgent need for alternative treatment strategies. 6
Our patient had longstanding plaque psoriasis and joint symptoms consistent with PsA, confirmed by clinical findings and imaging. Her condition remained active despite appropriate trials of topical corticosteroids, calcipotriene, and oral apremilast, and she declined methotrexate due to concern about side effects. Following initiation of semaglutide for metabolic indications, she experienced rapid and sustained improvement in both joint and skin symptoms, despite only modest weight loss at the time of initial symptom resolution. to rheumatology for further evaluation. Imaging of the hands revealed mild joint space narrowing at multiple distal interphalangeal joints with small marginal erosions and periosteal reaction, findings supportive of psoriatic arthritis( PsA). Methotrexate was discussed as a treatment option, but the patient declined due to concern about side effects. Her presentation was considered to be consistent with PsA. Photographs provided by the patient illustrate the condition of her hands prior to treatment( Figure 1).
Within two weeks of initiating semaglutide at the starting dose of 0.25 mg weekly, the patient reported near-complete resolution of her joint and skin symptoms. At her six-month follow-up, after titration to 0.5 mg, she had sustained this improvement, achieved a 20-pound weight loss, and maintained glycemic control. Follow-up photographs taken in the clinic six months after starting semaglutide therapy demonstrate the significant improvement in her hand condition( Figure 2).
The mechanism behind this improvement may involve GLP-1 RA – mediated suppression of pro-inflammatory cytokines such as TNF-α and IL-1β. Recent studies have demonstrated that GLP-1 RAs can reduce circulating levels of these pro-inflammatory cytokines and may lead to a reduction in oxidative stress. 3, 7 While weight loss is known to improve inflammatory disease activity, particularly in psoriatic disease, the benefits observed in this case appeared disproportionately rapid relative to the degree of adipose reduction. Notably, even modest
26 • www. wvsma. org